News Releases

OTCQB: INTI
PRICE:
Stock Info
Advanced Search
  • Dec 17, 2018
    HPPI to transfer SUBA-Itraconazole BCCNS clinical program to Mayne Pharma in consideration of up to $5 million in new funding from Mayne Pharma and a 9% royalty on future SUBA-Itraconazole BCCNS sales in the U.S. With new funding, HPPI to move towards IND filing during 2019 and recruitment to initiate human trials for SUBA-Itraconazole Prostate HPPI also to pursue expansion of product candidate pipeline with non-SUBA itraconazole analogue technology with University of Connecticut

    FOR IMMEDIATE RELEASE -- TAMPA, FLORIDA (December 17, 2018) – HedgePath Pharmaceuticals, Inc. (OTCQB:HPPI) announced today that it has entered into a revised Supply and License Agreement (SLA)...

  • Aug 6, 2018
    FDA has confirmed HPPI’s clinical and regulatory pathway for SUBA BCCNS and provided further guidance for anticipated NDA submission

    FOR IMMEDIATE RELEASE -- TAMPA, FLORIDA (August 6, 2018) – HedgePath Pharmaceuticals, Inc. (OTCQB:HPPI), a clinical stage biopharmaceutical company that discovers, develops and plans to...

  • Jul 19, 2018
    Access to UCONN’s technology could create the potential for HPPI to expand its pipeline of clinical stage itraconazole-based cancer treatments

    FOR IMMEDIATE RELEASE -- TAMPA, FLORIDA (July 19, 2018) – HedgePath Pharmaceuticals, Inc. (OTCQB:HPPI), a clinical stage biopharmaceutical company that discovers, develops and plans to...

  • Jul 9, 2018
    Additional $1.6 million in preferred stock and warrant funding to support SUBA BCCNS regulatory program HPPI to meet with FDA this month to discuss proposed 2018 NDA filing

    FOR IMMEDIATE RELEASE -- TAMPA, FLORIDA (July 9, 2018) – HedgePath Pharmaceuticals, Inc. (OTCQB:HPPI), a clinical stage biopharmaceutical company that discovers, develops and plans to...

  • Jun 5, 2018
    HPPI preparing patient dossiers for a July face-to-face meeting with FDA with the goal of filing an NDA later in 2018 Additional promising clinical trial data also announced

    FOR IMMEDIATE RELEASE -- TAMPA, FLORIDA (June 5, 2018) – HedgePath Pharmaceuticals, Inc. (OTCQB:HPPI), a clinical stage biopharmaceutical company that discovers, develops and plans to...

Show 5102550100 per page
Get Important News and Updates by Email
* Required Fields